Stroke therapy See also Sec 1/Rev xx - Integrated Platelets, Hemostasis, and Thrombosis Aspirin MOA: antiplatelet agent (COX inhibitor -> irreversible platelet inactivation) Recurrent stroke prevention, also Rx acute stroke PK: mixed order clearance, 81mg or 325mg qd Tox: GI (eg gastritis), bleeding, renal (aff arteriole constr -> dec GFR) Ticlopidine MOA: antiplatelet agent (irrev inhibition of ADP-induced platelet aggregation) Declining use but may be slightly better than aspirin Tox: diarrhea, leukopenia* (CBC after 3 mo) Clopidogrel (plavix TM) MOA: antiplatelet agent (irrev inhibition of ADP-induced platelet aggregation) Slightly better than aspirin for secondary stroke prevention Tox: fewer than ticlopidine (no leukopenia), rare TTP* Dipyridamole MOA: antiplatelet agent (PDE inhibitor -> dec aggregation) Ineffective alone (use with aspirin or warfarin) Aggrenox: sustained release dipyridamole + aspirin to Rx secondary stroke prevention Abciximab (ReoPro TM) MOA: antiplatelet agent (mAb Fab fragment against platelet glycoprotein IIb-IIIa) Rx unstable angina, off-label Rx stroke (under evaluation) Heparin MOA: anti-coagulant (glycosaminoglycan mixture activating antithrombin III) Clot formation prevention (eg Rx crescendo TIA) No role in acute stroke Rx (NOT thrombolytic) PK: IV or SQ only Tox: hemorrhage (follow w/ PTT), antidote protamine Low MW Heparinoids (lovenox TM or fragmin TM) MOA: anti-coagulant (low MW fraction of heparin) PK: fixed dose Blood test: consider factor Xa Warfarin (coumadin TM) MOA: anti-coagulant (blocks vitamin K dependent clotting factors) Slow onset (use heparin to tie over) PK: oral, high protein bound -> many drug interactions Tox: close monitoring (PT or INR), antidote fresh frozen plasma tPA (activase TM or alteplase TM) MOA: thrombolytic (human enzyme cleaves plasminogen into plasmin) Rx stroke w/in 3 hr of onset PK: IV or IA Tox: MANY contraindications -> use w/ caution Urokinase MOA: thrombolytic (human enzyme cleaves plasminogen to plasmin) Not in use anymore